摘要
目的探讨厄贝沙坦治疗高血压糖尿病对血压及尿蛋白的影响。方法选择108例符合高血压糖尿病诊断标准的患者随机分成两组,氨氯地平对照组和厄贝沙坦观察组各54例,治疗前后的血压、尿蛋白作比较分析。结果观察组和对照组α-微球蛋白分别降了(16.9±6.3)mg/L、(7.6±9.6)mg/L,尿微量白蛋白降幅分别是(19.6±7.0)mg/L、(12.1±4.4)mg/L,两组比较差异有统计学意义(p<0.01)。两组血压均有不同程度的下降,观察组明显,比较差异显著(p<0.05)。两组心率变化无统计学意义。结论厄贝沙坦有明显的降压和降尿蛋白的作用,是治疗高血压合并糖尿病较理想的药物。
Objective To study the infulence of irbesartan treatment on blood pressure and urinary protein excretion in the patients with hypertension and diabetes mellitus. Methods 108 patients who are diagnosed to have hypertension and diabetes mellitus were randomly divided into two groups： amlodipine group and irbesartan treatment groups. Compare blood pressure and urinary protein analysis before and after treatment to study the impact of irbesar- tan treatment. Results The irbesartan group and the control group alpha mieroglohulin were, repeetively, decreased by （ 16.9± 6.3 ） mg/L and （7.6 ±9.6） mg/L. moreover, microalbuminuria also decline （ 19.6±7. 0） mg/L and （ 12.1±4.4） mg/L,there were significant differences between the two groups （p 〈0. 01 ）. The blood pressure of two groups were decreased in different degree, the treatment group was more, the difference of the two groups is significant （p 〈 0.05）. The two groups had no significant changes in heart rate. Conclusion Irbesartan, which has obvious reduction effect on blood pressure and urinary protein, is a relatively ideal drug for the treatment of hypertension patients complicated with diabetes mellitus.
出处
《现代医院》
2012年第9期30-32,共3页
Modern Hospitals
关键词
厄贝沙坦
高血压
糖尿病
尿蛋白
Irbesartan, Hypertension, Diabetes, Urinary protein
